PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations
PROGECT is a registry for patients with Triple Negative breast cancer (TNBC) or patients who have an identified germline mutations (such as a mutation on the BRCA1 or BRCA2 genes).
⁃ Triple Negative Breast Cancer
• ER/PR \<10% and HER negative per current ASCO/CAP guidelines
• Stages I-IV
• Any age at diagnosis
• Patient must be within 5 years of diagnosis
• Eligible regardless of genetic testing status
• Genetic testing recommended for patients meeting NCCN and Medicare guidelines
⁃ AND/OR
⁃ Germline mutation Carriers
• Patients with deleterious or uncertain mutations in HBOC genes (BRCA, PTEN, P53, -PALB2 etc) are eligible regardless of type/site of cancer
• Healthy patients harboring mutations also eligible
• There is no time limit from the time of diagnosis of cancer and enrollment.
• Eligible regardless of personal history of cancer